一项多中心、随机、单盲、双臂干预研究:评估不可逆电穿孔消融局限性中低危前列腺癌后的不良事件与生活质量
本研究将局限性中低危前列腺癌患者随机分配至局灶或扩大不可逆电穿孔消融组,比较两组不良反应、患者报告生活质量及早期肿瘤学控制。中位随访30个月,两组勃起功能障碍和不良事件发生率相似;局灶消融组在3个月时国际勃起功能指数评分似乎更优,EPIC性功能评分随时间优于扩大消融组但接近统计学显著性(平均差1.4;95%CI -0.13至2.9,P=0.073)。6个月活检残留临床显著前列腺癌(Gleason≥3+4)率局灶组18.8% vs 扩大组13.2%,无显著差异。结论:两种消融方式安全性、排尿功能和肿瘤学结局相似,局灶消融在头3-6个月勃起功能结局优于扩大不可逆电穿孔。
要点
- 局灶与扩大不可逆电穿孔消融的安全性、排尿功能及早期肿瘤学结局相似。
- 局灶消融组3个月时国际勃起功能指数评分似乎更优。
- 6个月活检残留临床显著前列腺癌率局灶组18.8% vs 扩大组13.2%,无显著差异。
核心结论
- 局灶与扩大不可逆电穿孔消融在局限性中低危前列腺癌男性中具有相似的安全性、排尿功能和肿瘤学结局。
- 局灶消融在头3-6个月勃起功能结局优于扩大不可逆电穿孔。
研究设计与样本
- 多中心、随机、单盲、双臂干预研究。
- 局限性中低危前列腺癌男性随机接受局灶或扩大不可逆电穿孔消融。
- 局灶组51例,扩大组55例;中位随访时间30个月。
主要发现
- 3个月时两组勃起功能障碍发生率和不良事件发生率相似。
- 局灶消融组3个月时国际勃起功能指数评分似乎更优。
- 局灶消融组EPIC性功能评分随时间优于扩大消融组,接近统计学显著性(平均差1.4;95%CI -0.13至2.9,P=0.073)。
- 两组其他生活质量指标无显著差异。
- 6个月前列腺活检残留临床显著前列腺癌(Gleason≥3+4)率局灶组18.8% vs 扩大组13.2%,无显著差异。
关键数值与推荐
- 残留临床显著前列腺癌定义为Gleason≥3+4。
- EPIC性功能评分平均差1.4(95%CI -0.13至2.9,P=0.073),未达统计学显著。
- 6个月活检残留临床显著前列腺癌率局灶组18.8% vs 扩大组13.2%,无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our goal was to evaluate the effect of focal vs extended irreversible electroporation on side effects, patient-reported quality of life, and early oncologic control for localized low-intermediate risk prostate cancer patients. MATERIALS AND METHODS: Men with localized low-intermediate risk prostate cancer were randomized to receive focal or extended irreversible electroporation ablation. Quality of life was measured by International Index of Erectile Function, Expanded Prostate Cancer Index Composite questionnaire, and International Prostate Symptom Score. RESULTS: A total of 51 and 55 patients underwent focal and extended irreversible electroporation, respectively. The median follow-up time was 30 months. Rates of erectile dysfunction and rates of adverse events were similar between the 2 groups at 3 months. The focal ablation group seemed to have better International Index of Erectile Function scores at 3 months; it also had a better Expanded Prostate Cancer Index Composite-sexual function score than the extended ablation group across time that was close to statistical significance (mean difference 1.4; 95% CI -0.13 to 2.9, P = .073). There were no significant differences between the 2 groups in other quality-of-life measures. Upon prostate biopsy at 6 months, the rate of residual clinically significant prostate cancer (Gleason ≥3 + 4) was 18.8% and 13.2% in the focal and extended irreversible electroporation groups, respectively, without significant differences. CONCLUSIONS: Focal and extended irreversible electroporation ablation had similar safety profile, urinary function, and oncologic outcomes in men with localized low-intermediate risk prostate cancer. In addition, focal ablation demonstrated superior erectile function outcome over extended irreversible electroporation in the first 3-6 months.
引用
- de la Rosette J, Dominguez-Escrig J, Zhang K, et al. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. J Urol. 2022. PMID: 36441776. doi:10.1097/JU.0000000000003051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。